(289) Peptide-Guided Nanoparticles for Targeted Temozolomide Delivery in Glioblastoma

Introduction: Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor, with limited treatment options and a poor 5-year survival rate of only 5%. Chemotherapy with temozolomide is limited by the systemic toxicity and occurred resistance of the drug. Temozolomide (TMZ) based nanomedicine, in combination with precision and high affinity targeting with GBM-homing peptides, represents a promising strategy for selective GBM therapy in xenograft murine model of GBM.

Antonelal Rocchi – PhD student, Pharmacy, University of Chieti - Pescara "G. d'Annunzio"; Valeria Sidorenko – PhD student, University of Tartu; Maarja Haugas – PhD, University of Tartu; Allan Tobi – PhD, University of Tartu; Luca Marchetti – Post-doc, University of Tartu; Nicola d'Avanzo – Researcher, University of Catnazaro "Magna Graecia"; Massimo Fresta – Full professor, University of Catanzaro "Magna Graecia"; Tambet Teesalu – Full professor, University of Tartu